Search

Your search keyword '"Braunschweig I"' showing total 6 results
Start Over Author "Braunschweig I" Journal hematological oncology
6 results on '"Braunschweig I"'

1. OUTCOMES OF PATIENTS ≥ 65 YEARS OF AGE IN ZUMA-1, A PIVOTAL PHASE 1/2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN REFRACTORY LARGE B CELL LYMPHOMA

Author

Neelapu, S.S., primary, Jacobson, C.A., additional, Oluwole, O.O., additional, Munoz, J., additional, Deol, A., additional, Miklos, D.B., additional, Bartlett, N.L., additional, Braunschweig, I., additional, Jiang, Y., additional, Kim, J.J., additional, Zheng, L., additional, Rossi, J.M., additional, and Locke, F.L., additional

Published
2019
Full Text
View/download PDF

3. EXCEPTIONAL RESPONSE OF REFRACTORY ATLL WITH MDM4 AMPLIFICATION TO NOVEL STAPLED PEPTIDE DUAL MDM4/2 INHIBITOR

Author

Janakiram, M., primary, Ye, H.B., additional, Carjaval, L., additional, Villaorduna, A., additional, Ramesh, K., additional, Shah, U., additional, Kornblum, N., additional, Fehn, K., additional, Braunschweig, I., additional, Ueda, K., additional, Thiruthuvanathan, V., additional, Will, B., additional, Pinchasik, D., additional, Aivado, M., additional, Goel, S., additional, Steidl, U., additional, and Verma, A.K., additional

Published
2019
Full Text
View/download PDF

4. AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1

Author

Neelapu, S.S., primary, Locke, F.L., additional, Bartlett, N.L., additional, Lekakis, L.J., additional, Miklos, D., additional, Jacobson, C.A., additional, Braunschweig, I., additional, Oluwole, O., additional, Siddiqi, T., additional, Lin, Y., additional, Timmerman, J., additional, Reagan, P., additional, Navale, L., additional, Jiang, Y., additional, Aycock, J., additional, Elias, M., additional, Wiezorek, J., additional, and Go, W.Y., additional

Published
2017
Full Text
View/download PDF

5. PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

Author

Neelapu, S.S., primary, Rossi, J.M., additional, Locke, F.L., additional, Xue, A., additional, Better, M., additional, Zhang, X., additional, Ghobadi, A., additional, Lekakis, L.J., additional, Miklos, D., additional, Jacobson, C.A., additional, Braunschweig, I., additional, Oluwole, O., additional, Siddiqi, T., additional, Lin, Y., additional, Timmerman, J., additional, Reagan, P.M., additional, Navale, L., additional, Go, W.Y., additional, Wiezorek, J., additional, and Bot, A., additional

Published
2017
Full Text
View/download PDF

6. NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL).

Author

Bachy, E., Ramakrishnan, A., Thieblemont, C., Alfonso, A., Braunschweig, I., Riedell, P. A., Cartron, G., Barba, P., Gastinne, T., Simon, J. A. Perez, Solano, C., Meadows, S., LaCroce, A., Thomas, D., Poirot, C., Newhall, K. J., Lee, D. J., Frattini, M. G., and Abramson, J.

Subjects
CD19 antigen, NON-Hodgkin's lymphoma, T cells, CD20 antigen, STOCK ownership, CHIMERIC antigen receptors
Abstract

Eligibility criteria include age 18-80y, lymphoma cell expression of either or both CD20 and CD22, and >= 2 prior treatment regimens including autologous CD19 CAR T-cell therapy if eligible. NATHALI-01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (NHL) B Introduction: b Autologous CAR T-cell therapies have been transformative in the treatment of selected blood cancers. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results